Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1696125

registered interest
date	14/03/2024
answering body	Department for Transport
answering dept id	27
answering dept short name	Transport
answering dept sort name	Transport
hansard heading	Housing Estates: Construction
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Transport, what information his Department holds on the average timeframe for local authorities to enter into section 38 agreements from when they are first proposed.
tabling member constituency	Mid Bedfordshire
tabling member printed	Alistair Strathern
uin	18824
answer	answer is ministerial correction date of answer 18/03/2024 answer text <p>The Department does not hold information on this matter. Local highway authorities do not have to inform the Department when they enter into agreements of this sort.</p> answering member constituency Hexham answering member printed Guy Opperman question first answered 18/03/2024 14:15:19 answering member 4142 label Biography information for Guy Opperman
tabling member	5000 label Biography information for Alistair Strathern

1696126

registered interest
date	14/03/2024
answering body	Department for Levelling Up, Housing and Communities
answering dept id	211
answering dept short name	Levelling Up, Housing and Communities
answering dept sort name	Levelling Up, Housing and Communities
hansard heading	Housing Estates: Construction
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Levelling Up, Housing and Communities, what discussions he has had with local authorities on ensuring that residents do not live on estates without completed works of estate adoption.
tabling member constituency	Mid Bedfordshire
tabling member printed	Alistair Strathern
uin	18825
answer	answer is ministerial correction date of answer 19/03/2024 answer text <p>Respecting the established framework of devolution of powers and responsibilities to local government it is mainly for developers and local planning authorities to agree appropriate managing and funding arrangements for developments with common areas or shared services. The Government is also closely examining the findings of the Competition and Market Authority report that was published on 26 February.</p><p>Simultaneously, the Government is making estate management companies more accountable to existing homeowners for how their money is spent. The Leasehold and Freehold Reform Bill will make sure that existing homeowners who pay estate management charges have the right to challenge their reasonableness and to go to the tribunal to appoint a substitute manager to manage the provision of services. On freehold estates reform more generally, we understand the strength of feeling on this issue and we are considering it further.</p> answering member constituency North East Derbyshire answering member printed Lee Rowley question first answered 19/03/2024 16:01:39 answering member 4652 label Biography information for Lee Rowley
tabling member	5000 label Biography information for Alistair Strathern

1696127

registered interest
date	14/03/2024
answering body	Home Office
answering dept id	1
answering dept short name	Home Office
answering dept sort name	Home Office
hansard heading	Public Expenditure
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for the Home Department, whether the additional funding provided to the police in the Spring Budget 2024, HC 560, published on 6 March 2024, will have a consequential impact on the police allocation formula.
tabling member constituency	Mid Bedfordshire
tabling member printed	Alistair Strathern
uin	18826
answer	answer is ministerial correction date of answer 18/03/2024 answer text <p>The Government has announced an additional £234m will be invested in police productivity over the next four years.</p><p>This funding will be used to pilot or roll out cutting-edge technology such as live facial recognition, automation and the use of drones as first responders. It will also set up a Centre for Police Productivity to support police forces’ use of data and deliver this technology, maximising productivity and the use of AI.</p><p>Funding will be distributed to specific programmes and we are working with policing partners to allocate this funding. This funding will help all forces to free-up police officer time and improve performance.</p> answering member constituency Croydon South answering member printed Chris Philp question first answered 18/03/2024 17:21:59 answering member 4503 label Biography information for Chris Philp
tabling member	5000 label Biography information for Alistair Strathern

1696135

registered interest
date	14/03/2024
answering body	Ministry of Justice
answering dept id	54
answering dept short name	Justice
answering dept sort name	Justice
hansard heading	Prisoners' Release
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Justice, what discussions his Department had with (a) probation officers, (b) senior probation officers and (c) trade union officials representing probation officers before announcing the extension of the end of custody supervised license scheme.
tabling member constituency	Brentford and Isleworth
tabling member printed	Ruth Cadbury
uin	18724
answer	answer is ministerial correction date of answer 19/03/2024 answer text <p>The End of Custody Supervised License (ECSL) Scheme is a targeted measure that will operate in certain areas for a limited period of time where we are moving a prisoner’s release date earlier. We are committed to continue working with the police, prisons, and probation leaders to make further adjustments as required.</p><p> </p><p>Prior to the announcement in Parliament of the extension of ECSL on 11 March, Senior Regional Prison and Probation leaders and Trade Unions were advised of the decision to extend ECSL, to prepare to implement the ECSL changes effectively.</p> answering member constituency Charnwood answering member printed Edward Argar question first answered 19/03/2024 11:23:31 answering member 4362 label Biography information for Edward Argar
tabling member	4389 label Biography information for Ruth Cadbury

1696153

registered interest
date	14/03/2024
answering body	Department for Science, Innovation and Technology
answering dept id	216
answering dept short name	Science, Innovation and Technology
answering dept sort name	Science, Innovation and Technology
hansard heading	Semiconductors
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Science, Innovation and Technology, what steps she is taking to ensure regional representation on the UK Semiconductor Advisory Panel.
tabling member constituency	East Londonderry
tabling member printed	Mr Gregory Campbell
uin	18678
answer	answer is ministerial correction date of answer 19/03/2024 answer text <p>I refer the Hon. Member to the answer the previous Minister for Tech and Digital Economy gave on <a href="https://questions-statements.parliament.uk/written-questions/detail/2023-10-18/203233" target="_blank">23 October 2023.</a> In setting up the UK Semiconductor Advisory Panel, the government aimed for a small, focused group while ensuring representation across the semiconductor supply chain, UK domestic strengths, geographical locations and company size. We continue to speak with the full spectrum of the UK’s semiconductor industry, including regular engagement with companies and representatives from across the UK.</p> answering member constituency Meriden answering member printed Saqib Bhatti question first answered 19/03/2024 16:06:25 answering member 4818 label Biography information for Saqib Bhatti
tabling member	1409 label Biography information for Mr Gregory Campbell

1696166

registered interest
date	14/03/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medicines and Healthcare products Regulatory Agency: Standards
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether she plans to take steps to help increase productivity in the Medicines and Healthcare products Regulatory Agency.
tabling member constituency	York Central
tabling member printed	Rachael Maskell
uin	18748
answer	answer is ministerial correction date of answer 19/03/2024 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) regulates medicines, medical devices, and blood components for transfusion in the United Kingdom. It achieves this through the expertise of its staff, and its assets of ground-breaking science, innovative regulation, and real-world data.</p><p> </p><p>Ministers receive regular updates on the performance of the MHRA. The agency is taking significant steps to assess licensing applications within the shortest time possible. It is working to reduce timelines by bringing in additional resources and developing processes that will result in significantly improved response times, while protecting patient safety. As an effective regulator, it is committed to the highest of standards of performance, and delivering the right outcomes for patients and public health. These changes are already resulting in improvements.</p><p> </p><p>The Department holds the MHRA to account for their work, including their performance and the impact of any organisational changes, through regular established mechanisms including quarterly and annual accountability reviews. The minutes of the latest Annual Accountability Review with the MHRA are available at the following link:</p><p> </p><p><a href="https://www.gov.uk/government/publications/annual-accountability-review-mhra/annual-accountability-review-minutes-2022-to-2023-3-july-2023" target="_blank">https://www.gov.uk/government/publications/annual-accountability-review-mhra/annual-accountability-review-minutes-2022-to-2023-3-july-2023</a></p><p> </p><p>The MHRA also publishes performance figures each month, and annually through their annual report and accounts. As set out in its 2023-26 Corporate Plan, the MHRA is committed to delivering predictable, optimised, and sustainable services, across all functions.</p><p> </p><p>As part of the 2023 Spring Budget, the MHRA also received £10 million of additional funding. This is to support the acceleration of routes for bringing innovative medical products developed in the UK onto the market, allowing the MHRA to capitalise on the expertise and decision-making of trusted regulatory partners. The Government is committed to supporting the MHRA to meet its statutory obligations.</p><p> </p><p>The Department receives regular feedback from a wide range of stakeholders. In 2023 the Department did receive representations from the scientific community, and industry, expressing concern about delays in the MHRA’s approvals of clinical trials. The MHRA has since improved its performance in this area, and there are currently no delays in approving clinical trials.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 18749 18750 18751 18752 question first answered 19/03/2024 14:36:18 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4471 label Biography information for Rachael Maskell

1696174

registered interest
date	14/03/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medicines and Healthcare products Regulatory Agency
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps she is taking to help increase the capacity of the Medicines and Healthcare products Regulatory Agency.
tabling member constituency	York Central
tabling member printed	Rachael Maskell
uin	18749
answer	answer is ministerial correction date of answer 19/03/2024 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) regulates medicines, medical devices, and blood components for transfusion in the United Kingdom. It achieves this through the expertise of its staff, and its assets of ground-breaking science, innovative regulation, and real-world data.</p><p> </p><p>Ministers receive regular updates on the performance of the MHRA. The agency is taking significant steps to assess licensing applications within the shortest time possible. It is working to reduce timelines by bringing in additional resources and developing processes that will result in significantly improved response times, while protecting patient safety. As an effective regulator, it is committed to the highest of standards of performance, and delivering the right outcomes for patients and public health. These changes are already resulting in improvements.</p><p> </p><p>The Department holds the MHRA to account for their work, including their performance and the impact of any organisational changes, through regular established mechanisms including quarterly and annual accountability reviews. The minutes of the latest Annual Accountability Review with the MHRA are available at the following link:</p><p> </p><p><a href="https://www.gov.uk/government/publications/annual-accountability-review-mhra/annual-accountability-review-minutes-2022-to-2023-3-july-2023" target="_blank">https://www.gov.uk/government/publications/annual-accountability-review-mhra/annual-accountability-review-minutes-2022-to-2023-3-july-2023</a></p><p> </p><p>The MHRA also publishes performance figures each month, and annually through their annual report and accounts. As set out in its 2023-26 Corporate Plan, the MHRA is committed to delivering predictable, optimised, and sustainable services, across all functions.</p><p> </p><p>As part of the 2023 Spring Budget, the MHRA also received £10 million of additional funding. This is to support the acceleration of routes for bringing innovative medical products developed in the UK onto the market, allowing the MHRA to capitalise on the expertise and decision-making of trusted regulatory partners. The Government is committed to supporting the MHRA to meet its statutory obligations.</p><p> </p><p>The Department receives regular feedback from a wide range of stakeholders. In 2023 the Department did receive representations from the scientific community, and industry, expressing concern about delays in the MHRA’s approvals of clinical trials. The MHRA has since improved its performance in this area, and there are currently no delays in approving clinical trials.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 18748 18750 18751 18752 question first answered 19/03/2024 14:36:18 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4471 label Biography information for Rachael Maskell

1696185

registered interest
date	14/03/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medicines and Healthcare products Regulatory Agency: Standards
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether she has received representations from the scientific community on the efficiency of the Medicines and Healthcare products Regulatory Agency.
tabling member constituency	York Central
tabling member printed	Rachael Maskell
uin	18750
answer	answer is ministerial correction date of answer 19/03/2024 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) regulates medicines, medical devices, and blood components for transfusion in the United Kingdom. It achieves this through the expertise of its staff, and its assets of ground-breaking science, innovative regulation, and real-world data.</p><p> </p><p>Ministers receive regular updates on the performance of the MHRA. The agency is taking significant steps to assess licensing applications within the shortest time possible. It is working to reduce timelines by bringing in additional resources and developing processes that will result in significantly improved response times, while protecting patient safety. As an effective regulator, it is committed to the highest of standards of performance, and delivering the right outcomes for patients and public health. These changes are already resulting in improvements.</p><p> </p><p>The Department holds the MHRA to account for their work, including their performance and the impact of any organisational changes, through regular established mechanisms including quarterly and annual accountability reviews. The minutes of the latest Annual Accountability Review with the MHRA are available at the following link:</p><p> </p><p><a href="https://www.gov.uk/government/publications/annual-accountability-review-mhra/annual-accountability-review-minutes-2022-to-2023-3-july-2023" target="_blank">https://www.gov.uk/government/publications/annual-accountability-review-mhra/annual-accountability-review-minutes-2022-to-2023-3-july-2023</a></p><p> </p><p>The MHRA also publishes performance figures each month, and annually through their annual report and accounts. As set out in its 2023-26 Corporate Plan, the MHRA is committed to delivering predictable, optimised, and sustainable services, across all functions.</p><p> </p><p>As part of the 2023 Spring Budget, the MHRA also received £10 million of additional funding. This is to support the acceleration of routes for bringing innovative medical products developed in the UK onto the market, allowing the MHRA to capitalise on the expertise and decision-making of trusted regulatory partners. The Government is committed to supporting the MHRA to meet its statutory obligations.</p><p> </p><p>The Department receives regular feedback from a wide range of stakeholders. In 2023 the Department did receive representations from the scientific community, and industry, expressing concern about delays in the MHRA’s approvals of clinical trials. The MHRA has since improved its performance in this area, and there are currently no delays in approving clinical trials.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 18748 18749 18751 18752 question first answered 19/03/2024 14:36:18 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4471 label Biography information for Rachael Maskell

1696188

registered interest
date	14/03/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medicines and Healthcare products Regulatory Agency: Finance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether she has made an assessment of the adequacy of funding provided to the Medicines and Healthcare products Regulatory Agency.
tabling member constituency	York Central
tabling member printed	Rachael Maskell
uin	18751
answer	answer is ministerial correction date of answer 19/03/2024 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) regulates medicines, medical devices, and blood components for transfusion in the United Kingdom. It achieves this through the expertise of its staff, and its assets of ground-breaking science, innovative regulation, and real-world data.</p><p> </p><p>Ministers receive regular updates on the performance of the MHRA. The agency is taking significant steps to assess licensing applications within the shortest time possible. It is working to reduce timelines by bringing in additional resources and developing processes that will result in significantly improved response times, while protecting patient safety. As an effective regulator, it is committed to the highest of standards of performance, and delivering the right outcomes for patients and public health. These changes are already resulting in improvements.</p><p> </p><p>The Department holds the MHRA to account for their work, including their performance and the impact of any organisational changes, through regular established mechanisms including quarterly and annual accountability reviews. The minutes of the latest Annual Accountability Review with the MHRA are available at the following link:</p><p> </p><p><a href="https://www.gov.uk/government/publications/annual-accountability-review-mhra/annual-accountability-review-minutes-2022-to-2023-3-july-2023" target="_blank">https://www.gov.uk/government/publications/annual-accountability-review-mhra/annual-accountability-review-minutes-2022-to-2023-3-july-2023</a></p><p> </p><p>The MHRA also publishes performance figures each month, and annually through their annual report and accounts. As set out in its 2023-26 Corporate Plan, the MHRA is committed to delivering predictable, optimised, and sustainable services, across all functions.</p><p> </p><p>As part of the 2023 Spring Budget, the MHRA also received £10 million of additional funding. This is to support the acceleration of routes for bringing innovative medical products developed in the UK onto the market, allowing the MHRA to capitalise on the expertise and decision-making of trusted regulatory partners. The Government is committed to supporting the MHRA to meet its statutory obligations.</p><p> </p><p>The Department receives regular feedback from a wide range of stakeholders. In 2023 the Department did receive representations from the scientific community, and industry, expressing concern about delays in the MHRA’s approvals of clinical trials. The MHRA has since improved its performance in this area, and there are currently no delays in approving clinical trials.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 18748 18749 18750 18752 question first answered 19/03/2024 14:36:18 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4471 label Biography information for Rachael Maskell

1696190

registered interest
date	14/03/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medicines and Healthcare products Regulatory Agency: Standards
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps she is taking to (a) monitor and (b) report on the performance of the Medicines and Healthcare Products Regulatory Agency.
tabling member constituency	York Central
tabling member printed	Rachael Maskell
uin	18752
answer	answer is ministerial correction date of answer 19/03/2024 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) regulates medicines, medical devices, and blood components for transfusion in the United Kingdom. It achieves this through the expertise of its staff, and its assets of ground-breaking science, innovative regulation, and real-world data.</p><p> </p><p>Ministers receive regular updates on the performance of the MHRA. The agency is taking significant steps to assess licensing applications within the shortest time possible. It is working to reduce timelines by bringing in additional resources and developing processes that will result in significantly improved response times, while protecting patient safety. As an effective regulator, it is committed to the highest of standards of performance, and delivering the right outcomes for patients and public health. These changes are already resulting in improvements.</p><p> </p><p>The Department holds the MHRA to account for their work, including their performance and the impact of any organisational changes, through regular established mechanisms including quarterly and annual accountability reviews. The minutes of the latest Annual Accountability Review with the MHRA are available at the following link:</p><p> </p><p><a href="https://www.gov.uk/government/publications/annual-accountability-review-mhra/annual-accountability-review-minutes-2022-to-2023-3-july-2023" target="_blank">https://www.gov.uk/government/publications/annual-accountability-review-mhra/annual-accountability-review-minutes-2022-to-2023-3-july-2023</a></p><p> </p><p>The MHRA also publishes performance figures each month, and annually through their annual report and accounts. As set out in its 2023-26 Corporate Plan, the MHRA is committed to delivering predictable, optimised, and sustainable services, across all functions.</p><p> </p><p>As part of the 2023 Spring Budget, the MHRA also received £10 million of additional funding. This is to support the acceleration of routes for bringing innovative medical products developed in the UK onto the market, allowing the MHRA to capitalise on the expertise and decision-making of trusted regulatory partners. The Government is committed to supporting the MHRA to meet its statutory obligations.</p><p> </p><p>The Department receives regular feedback from a wide range of stakeholders. In 2023 the Department did receive representations from the scientific community, and industry, expressing concern about delays in the MHRA’s approvals of clinical trials. The MHRA has since improved its performance in this area, and there are currently no delays in approving clinical trials.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 18748 18749 18750 18751 question first answered 19/03/2024 14:36:18 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4471 label Biography information for Rachael Maskell